Vanguard Global Advisers
OTLK icon

Vanguard Global Advisers’s Outlook Therapeutics OTLK Stock Holding History

Vanguard Global Advisers’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.4K Buy
41,137
+34,230
+496% +$21.2K ﹤0.01% 2967
2026
Q1 		$1.42K Buy
+6,907
New +$2.98K ﹤0.01% 3630

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's OTLK Position: Q2 2026 in Review

Vanguard Global Advisers increased its Outlook Therapeutics (OTLK) stake by 496% in Q2 2026, buying an estimated $21.2K and bringing the position to 41,137 shares worth $65.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2967.

Vanguard Global Advisers first reported a position in OTLK in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Vanguard Global Advisers held 41,137 shares of Outlook Therapeutics worth $65.4K as of Q2 2026.
  • Vanguard Global Advisers bought 34,230 Outlook Therapeutics shares in Q2 2026, an estimated $21.2K.
  • Outlook Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2967 holding.
  • Vanguard Global Advisers first reported a position in Outlook Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.